References
- Sohocki MM, Daiger SP, Bowne SJ, et al. Prevalence of mutations causing retinitis pigmentosa and other inherited retinopathies. Hum Mutat. 2001;17(1):42–51.
- LUXTURNATM (voretigene neparvovec-rzyl) December 19, 2017 approval letter; 2017. [cited 2020 Mar 14]. Available from: https://www.fda.gov/downloads/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/UCM589690.pdf
- Novartis announces landmark EU approval for one-time gene therapy Luxturna® to restore vision in people with rare inherited retinal disease; 2018 11-23-18. [cited 2020 Mar 14]. Available from: https://www.novartis.com/news/media-releases/novartis-announces-landmark-eu-approval-one-time-gene-therapy-luxturna-restore-vision-people-rare-inherited-retinal-disease
- LUXTURNA (voretigene neparvovec-rzyl) US Full prescribing information; 2017. [cited 2020 Mar 14]. Available from: http://sparktx.com/LUXTURNA_US_Prescribing_Information.pdf
- Moore NA, Morral N, Ciulla TA, et al. Gene therapy for inherited retinal and optic nerve degenerations. Expert Opin Biol Ther. 2018;18(1):37–49.
- Seitz IP, Michalakis S, Wilhelm B, et al. Superior retinal gene transfer and biodistribution profile of subretinal versus intravitreal delivery of AAV8 in nonhuman primates. Invest Ophthalmol Vis Sci. 2017;58(13):5792–5801.
- Streilein JW. Ocular immune privilege: therapeutic opportunities from an experiment of nature. Nat Rev Immunol. 2003;3(11):879–889.
- Wenkel H, Streilein JW. Analysis of immune deviation elicited by antigens injected into the subretinal space. Invest Ophthalmol Vis Sci. 1998;39(10):1823–1834.
- Russell S, Bennett J, Wellman JA, et al. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet. 2017;390(10097):849–860.
- Bennett J, Wellman J, Marshall KA, et al. Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial. Lancet. 2016;388(10045):661–672.
- Hanein S, Perrault I, Gerber S, et al. Leber congenital amaurosis: comprehensive survey of the genetic heterogeneity, refinement of the clinical definition, and genotype-phenotype correlations as a strategy for molecular diagnosis. Hum Mutat. 2004;23(4):306–317.
- Allikmets R. Leber congenital amaurosis: a genetic paradigm. Ophthalmic Genet. 2004;25(2):67–79.
- Chung DC, Bertelsen M, Lorenz B, et al. The natural history of inherited retinal dystrophy due to biallelic mutations in the RPE65 gene. Am J Ophthalmol. 2018;199:58–70.
- Hussain RM, Gregori NZ, Ciulla TA, et al. Pharmacotherapy of retinal disease with visual cycle modulators. Expert Opin Pharmacother. 2018;19(5):471–481.
- Lorenz B, Gyurus P, Preising M, et al. Early-onset severe rod-cone dystrophy in young children with RPE65 mutations. Invest Ophthalmol Vis Sci. 2000;41(9):2735–2742.
- Sengillo JD, Justus S, Tsai YT, et al. Gene and cell-based therapies for inherited retinal disorders: an update. Am J Med Genet C Semin Med Genet. 2016;172(4):349–366.
- Everson EM, Trobridge GD. Retroviral vector interactions with hematopoietic cells. Curr Opin Virol. 2016;21:41–46.
- Sakuma T, Barry MA, Ikeda Y. Lentiviral vectors: basic to translational. Biochem J. 2012;443(3):603–618.
- Zufferey R, Dull T, Mandel RJ, et al. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol. 1998;72(12):9873–9880.
- Kumar M, Keller B, Makalou N, et al. Systematic determination of the packaging limit of lentiviral vectors. Hum Gene Ther. 2001;12(15):1893–1905.
- Carter PJ, Samulski RJ. Adeno-associated viral vectors as gene delivery vehicles. Int J Mol Med. 2000;6(1):17–27.
- Day TP, Byrne LC, Schaffer DV, et al. Advances in AAV vector development for gene therapy in the retina. Adv Exp Med Biol. 2014;801:687–693.
- Daya S, Berns KI. Gene therapy using adeno-associated virus vectors. Clin Microbiol Rev. 2008;21(4):583–593.
- Surace EM, Auricchio A. Versatility of AAV vectors for retinal gene transfer. Vision Res. 2008;48(3):353–359.
- Hareendran S, Balakrishnan B, Sen D, et al. Adeno-associated virus (AAV) vectors in gene therapy: immune challenges and strategies to circumvent them. Rev Med Virol. 2013;23(6):399–413.
- Vandenberghe LH, Bell P, Maguire AM, et al. Dosage thresholds for AAV2 and AAV8 photoreceptor gene therapy in monkey. Sci Transl Med. 2011;3(88):88ra54.
- Summerford C, Samulski RJ. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol. 1998;72(2):1438–1445.
- United States Secturities and Exchange Commission, Form 10-Q, For the quarterly period ended September 30, 2018, spark therapeutics; 2018.
- Acland GM, Aguirre GD, Ray J, et al. Gene therapy restores vision in a canine model of childhood blindness. Nat Genet. 2001;28(1):92–95.
- Le Meur G, Stieger K, Smith AJ, et al. Restoration of vision in RPE65-deficient Briard dogs using an AAV serotype 4 vector that specifically targets the retinal pigmented epithelium. Gene Ther. 2007;14(4):292–303.
- Bainbridge JWB, Smith AJ, Barker SS, et al. Effect of gene therapy on visual function in Leber’s congenital amaurosis. N Engl J Med. 2008;358(21):2231–2239.
- Hauswirth WW, Aleman TS, Kaushal S, et al. Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. Hum Gene Ther. 2008;19(10):979–990.
- Maguire AM, Simonelli F, Pierce EA, et al. Safety and efficacy of gene transfer for Leber’s congenital amaurosis. N Engl J Med. 2008;358(21):2240–2248.
- Maguire AM, High KA, Auricchio A, et al. Age-dependent effects of RPE65 gene therapy for Leber’s congenital amaurosis: a phase 1 dose-escalation trial. Lancet. 2009;374(9701):1597–1605.
- Testa F, Maguire AM, Rossi S, et al. Three-year follow-up after unilateral subretinal delivery of adeno-associated virus in patients with Leber congenital Amaurosis type 2. Ophthalmology. 2013;120(6):1283–1291.
- Maguire AM, Russell S, Wellman JA, et al., Efficacy, safety, and durability of voretigene neparvovec-rzyl in RPE65 mutation-associated inherited retinal dystrophy: results of phase 1 and 3 trials. Ophthalmology. 126(9): 1273–1285. 2019.
- Jacobson SG, Cideciyan AV, Roman AJ, et al. Improvement and decline in vision with gene therapy in childhood blindness. N Engl J Med. 2015;372(20):1920–1926.
- Bainbridge JWB, Mehat MS, Sundaram V, et al. Long-term effect of gene therapy on Leber’s congenital amaurosis. N Engl J Med. 2015;372(20):1887–1897.
- Chung DC, McCague S, Yu Z-F, et al., Novel mobility test to assess functional vision in patients with inherited retinal dystrophies. Clin Exp Ophthalmol. 46(3): 247–259. 2018. .
- Spark therapeutics announces new positive data from continuation of phase 3 trial of voretigene neparvovec; 2016. [cited 2020 Mar 14]. Available from: https://sparktx.com/press_releases/spark-therapeutics-announces-new-positive-data-from-continuation-of-phase-3-trial-of-voretigene-neparvovec/
- Drack AV, Bennett J, Russell S, et al. How long does gene therapy last? 4-year follow up of phase 3 voretigene neparvovec trial in RPE65-associated LCA/inherited retinal disease. JAAPOS. 2019;23(4):e7.
- FDA approves spark therapeutics’ LUXTURNA™ (voretigene neparvovec-rzyl), a one-time gene therapy for patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy; 2017. [cited 2020 Mar 14]. Available from: https://sparktx.com/press_releases/fda-approves-spark-therapeutics-luxturna-voretigene-neparvovec-rzyl-a-one-time-gene-therapy-for-patients-with-confirmed-biallelic-rpe65-mutation-associated-retinal-dystrophy/
- Dalkara D, Kolstad KD, Caporale N, et al. Inner limiting membrane barriers to AAV-mediated retinal transduction from the vitreous. Mol Ther. 2009;17(12):2096–2102.
- Reichel FF, Peters T, Wilhelm B, et al. Humoral immune response after intravitreal but not after subretinal AAV8 in primates and patients. Invest Ophthalmol Vis Sci. 2018;59(5):1910–1915.
- Li Q, Miller R, Han PY, et al. Intraocular route of AAV2 vector administration defines humoral immune response and therapeutic potential. Mol Vis. 2008;14:1760–1769.
- Kotterman MA, Yin L, Strazzeri JM, et al. Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates. Gene Ther. 2015;22(2):116–126.
- Dalkara D, Byrne LC, Klimczak RR, et al. In vivo-directed evolution of a new adeno-associated virus for therapeutic outer retinal gene delivery from the vitreous. Sci Transl Med. 2013;5(189):189ra76.
- Petrs-Silva H, Dinculescu A, Li Q, et al. Novel properties of tyrosine-mutant AAV2 vectors in the mouse retina. Mol Ther. 2011;19(2):293–301.
- Mowat FM, Gornik KR, Dinculescu A, et al. Tyrosine capsid-mutant AAV vectors for gene delivery to the canine retina from a subretinal or intravitreal approach. Gene Ther. 2014;21(1):96–105.
- Petrs-Silva H, Dinculescu A, Li Q, et al. High-efficiency transduction of the mouse retina by tyrosine-mutant AAV serotype vectors. Mol Ther. 2009;17(3):463–471.
- Ding K, Shen J, Hafiz Z, et al. AAV8-vectored suprachoroidal gene transfer produces widespread ocular transgene expression. J Clin Invest. 2019;130:4901–4911.
- Yiu G, Chung CY, Mollhoff IN, et al. Suprachoroidal and subretinal injections of AAV using transscleral microneedles for retinal gene delivery in nonhuman primates. Mol Ther. 2020;16:179–191.
- Hussain RM, Tran KD, Maguire AM, et al. Subretinal injection of voretigene neparvovec-rzyl in a patient with RPE65-associated Leber’s congenital amaurosis. Ophthalmic Surg Lasers Imaging Retina. 2019;50(10):661–663.
- RetNet: summaries of genes and loci causing retinal diseases. [cited 2020 Mar 14]. Available from: https://sph.uth.edu/retnet/sum-dis.htm
- ID Your IRD, no charge genetic testing for inherited retinal diseases (IRDs). [cited 2020 Mar 14]. Available from: https://www.invitae.com/en/idyourird/
- Mahajan VB, Bennett J, Maguire A, et al. RPE65 mutation subtype effect on baseline visual function and treatment response in phase 3 voretigene neparvovec trial. In: American academy of ophthalmology. A presentation delivered at the October 2018 annual meeting of the American Academy of Ophthalmology, Chicago; 2018.
- Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American college of medical genetics and genomics and the association for molecular pathology. Genet Med. 2015;17(5):405–424.
- The John and Marcia carver nonprofit genetic testing laboratory. estimating pathogenic probability; 2020. [cited 2020 Mar 14]. Available from: https://www.carverlab.org/interpretation/estimation
- Yang U, Gentleman S, Gai X, et al. Utility of in vitro mutagenesis of RPE65 protein for verification of mutational pathogenicity before gene therapy. JAMA Ophthalmol. 2019;1–9.
- Orphan drug act; 1983. Jan. 4, 1983; 21 U.S.C., Ch. 9, Subch. V, Part B, §§ 360aa-360ff1, as amended]. [cited 2020 Mar 14]. Available from: https://www.fda.gov/downloads/ForIndustry/DevelopingProductsforRareDiseasesConditions/HowtoapplyforOrphanProductDesignation/UCM517741.pdf
- Regulation (EC) No 141/2000 of the European parliament and of the council of 16 December 1999 on orphan medicinal products; 2000. [cited 2020 Mar 14]. Available from: https://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2000:018:0001:0005:en:PDF
- Spark therapeutics receives rare pediatric disease designation for investigational LUXTURNA™ (voretigene neparvovec) from FDA; 2017. [cited 2020 Mar 14]. Available from: https://sparktx.com/press_releases/spark-therapeutics-receives-rare-pediatric-disease-designation-for-investigational-luxturna-voretigene-neparvovec-from-fda/
- Spark therapeutics sells priority review voucher for $110 million; 2018. [cited 2020 Mar 14]. Available from: https://sparktx.com/press_releases/spark-therapeutics-sells-priority-review-voucher-for-110-million/
- Safety study in subjects with leber congenital amaurosis; 2007 [cited 2020 Mar 14]. Available from: https://clinicaltrials.gov/ct2/show/NCT00516477
- Spark therapeutics announces positive top-line results from pivotal phase 3 trial of SPK-RPE65 for genetic blinding conditions; 2015 Oct 05. [cited 2020 Mar 14]. Available from: https://sparktx.com/press_releases/spark-therapeutics-announces-positive-top-line-results-from-pivotal-phase-3-trial-of-spk-rpe65-for-genetic-blinding-
- LUXTURNA is only administered at ocular gene therapy treatment centers. [cited 2020 Mar 14]. Available from: https://mysparkgeneration.com/hcp-support.html#TreatmentCenters
- Johnson S, Buessing M, O’Connell T, et al. Cost-effectiveness of voretigene neparvovec-rzyl vs standard Care for RPE65-mediated inherited retinal disease. JAMA Ophthalmol. 2019;137(10):1115–1123.
- Buessing M, O’Connell T, Johnson S, et al. Important considerations in modeling the cost-effectiveness for the first food and drug administration-approved gene therapy and implications for future one-time therapies. Value Health. 2019;22(8):970–971.
- Lloyd A, Piglowska N, Ciulla T, et al. Estimation of impact of RPE65-mediated inherited retinal disease on quality of life and the potential benefits of gene therapy. Br J Ophthalmol. 2019;103(11):1610–1614.
- Brown MM, Brown GC, Sharma S, et al. Health care economic analyses and value-based medicine. Surv Ophthalmol. 2003;48(2):204–223.
- Brown GC, Brown MM, Sharma S, et al. The burden of age-related macular degeneration: a value-based medicine analysis. Trans Am Ophthalmol Soc. 2005;103:173–184. discussion 184-6.
- Severens JL, Milne RJ. Discounting health outcomes in economic evaluation: the ongoing debate. Value Health. 2004;7(4):397–401.
- Spark therapeutics announces first-of-their-kind programs to improve patient access to LUXTURNA™ (voretigene neparvovec-rzyl), a one-time gene therapy treatment; 2018. [cited 2020 Mar 14]. Available from: https://sparktx.com/press_releases/spark-therapeutics-announces-first-of-their-kind-programs-to-improve-patient-access-to-luxturna-voretigene-neparvovec-rzyl-a-one-time-gene-therapy-treatment/
- Moore NA, Bracha P, Hussain RM, et al. Gene therapy for age-related macular degeneration. Expert Opin Biol Ther. 2017;17(10):1235–1244.
- Cideciyan AV, Jacobson SG, Beltran WA, et al. Human retinal gene therapy for Leber congenital amaurosis shows advancing retinal degeneration despite enduring visual improvement. Proc Natl Acad Sci U S A. 2013;110(6):E517–E525.